Abstract
INTRODUCTION
Heart transplantation has been the best therapeutic option for endstage heart failure for more than 40 years, since the first cardiac transplantation performed in 1967 by Christiaan N. Barnard. A downside to this success has been the increasing demand for donor hearts, leading to an unbridgeable gap between organ demand and supply. Donor allocation systems, such as United Network for Organ Sharing (UNOS) or Eurotransplant, are ruled by medical urgency, in order to prioritize more urgent recipients. After reflection on an increasing mortality in the waiting list for cardiac transplantation, a high-urgency waiting list was opened in France in 2004: Special Urgency1 (SU1) status was granted for 48 h, renewable once, to critically ill patients. To date, reports about outcomes of patients transplanted according to the SU1 priority status are still limited to small series [1, 2] whereas results of Eurotransplant high urgency heart allocation system remain controversial [3, 4] .
In our Institution, the first transplantation according the SU1 criteria was performed in July 2004. Since then, facing the relative shortage of organ donors, the SU1 waiting list allowed allocating cardiac donors for critically ill patients: we analysed our singlecentre 8-year experience, in order to evaluate the impact of SU1 high-urgency priority on early mortality and mid-term survival, in comparison with standard list transplantations.
METHODS

Study population
A retrospective analysis involved 265 patients, who met the criteria for high-urgency SU1 waiting list inscription, between 1 January 2005 and 31 December 2012. Among them, 212 patients underwent cardiac transplantation according to the SU1 priority status (SU1 group). They were compared with 297 cardiac recipients who underwent transplantation according to standard donor allocation (Standard List group, SL group). Fifty-two patients under long-term ventricular assist device (VAD) support at the time of transplantation were not included in the study, because most of them were listed according to SU2 priority status. Fifty-three patients missed donor allocation during the SU1 status period, and they were downgraded to the standard waiting list at the end of the renewed 48-h frame time of high-urgency national priority. Donor as well as recipient data were obtained from 'Cristal', French regulatory agency database for transplantation, the 'Agence de la Biomedicine'. An institutional prospective digital database system (DxCare, Medasys Corporation) was also used as complementary data source. An Institutional Review Board grant was released by the ethical committee of the French Society of Thoracic and Cardiovascular Surgery (CERC-SFCTCV-2014-7-23-13-11-16-D4CO).
Special urgency donor allocation algorithm
Special Urgency1 status was granted for 48 h, renewable once, to critically ill patients requiring continuous infusion of intravenous inotropic drugs, with or without extracorporeal membrane oxygenator or intra-aortic balloon pump support, in whom a VAD or total artificial heart (TAH) was indicated in order to avoid the bridge-to-bridge step and directly move towards transplantation; catecholamine dosage required to allow SU1 status is dobutamine 10 mg/kg/min or epinephrine (or norepinephrine) 0.1 mg/kg/min. SU2 status was granted to patients implanted with long-term mechanical circulatory support and experiencing device-related thromboembolism or infection refractory to antibiotic therapy. Although the SU2 status has less priority than SU1, it can be renewed until transplantation is to be performed. Recently, a SU3 status was added for stable, non-complicated patients under biventricular paracorporeal pneumatic support or TAH.
Available donor hearts were offered first to SU1 patients, then to SU2 and SU3 patients, and finally to standard waiting list patients according to geographic criteria [5] .
Definitions and outcomes
Primary outcomes included the occurrence of severe primary graft failure (PGF) needing an Extra-Corporeal Membrane Oxygenation (ECMO) support in the immediate postoperative 48-h period, 1-year mortality, 1-year and 5-year survival rates.
Statistical analyses
Univariate analysis was performed using Chi-square and Fisher's exact tests for categorical variables; an unpaired t-test was used for normally distributed data, after assessment of equality of variances. In addition, the Mann-Whitney U-test was used. A propensity score was built in order to make the two groups more comparable: a logistic regression model was performed to create a propensity score, in which priority status (SL or SU1 group) was the dependent variable. Variables used to determine the propensity score were selected among preoperative recipient and donor variables that were different at a two-tailed nominal P-value of <0.10: recipient gender, preoperative ECMO, preoperative Implantable Cardioverter Defibrillator (ICD), recipient non-insulin-dependent diabetes, ventilator-dependent recipient, inotrope-dependent recipient, donor gender, gender mismatch, donor older than 50 years, donor above 60 years, trauma as cause of donor death, anoxic arrest as cause of donor death, weight mismatch >0.15, body surface area (BSA) >0.15, recipient age, recipient height, time on the waiting list, recipient BSA, recipient creatinine clearance, donor weight, donor height, donor BSA, height mismatch and ischaemic time.
Patients with a probability of being listed in the SU1 group <0.10 or >0.90, estimated by the logistic model, were then discarded for the second step, in order to make the two groups more homogenous. The remaining patients defined what we call the 'propensity selected groups'. The way we used the propensity score, that is the log-odds-ratio on probability to belong to the SU1 group, was to add it as a covariable in the second step, in which a stepwise logistic regression was performed to determine the prognostic factors of 1-year mortality. Variables selected for the stepwise logistic regression were those with a P-value lower than 0.10 in a univariate analysis. Propensity score and priority status were forced in the final model.
After discarding patients with a propensity score corresponding to a probability of being listed in the SU1 group <0.10 or >0.90, a stepwise logistic regression was performed to determine predictors for the occurrence of 1-year mortality, with a cut-off of P = 0.10. The propensity score was subsequently regressed as an independent covariate in the multivariable logistic regression model, including the priority status.
A subgroup analysis was carried out for all 212 SU1 patients. Three analyses were performed: in the first one, the prognostic factors of 1-year mortality were assessed using a logistic model. In a second analysis, the outcome was the 5-year survival. Survival curves were estimated by the Kaplan-Meier method and compared by the log-rank test. Continuous potential risk factors were tested by univariate Cox models. Variables with a P-value lower than 0.10 in the univariate analysis were selected for a stepwise Cox model regression. Variables with a P-value of the Wald test lower than 0.05 were retained in the final Cox model. The last analysis examined the period effect: the patients were divided into two groups, according to the date of transplantation: 2005-08 or 2009-12. The period effect was finally tested as a potential risk factor for 1-year mortality. To measure model discrimination, c-statistics (area under the receiver operating characteristic curve) were used, and the Hosmer-Lemeshow test was used for goodness-of-fit assessment.
Data are expressed as means ± standard deviations for continuous variables, and percentages for qualitative variables. All Pvalues were two-tailed.
All statistical analyses were performed with the SAS V9.3 statistical package.
RESULTS
During the study period, 38% of all transplantations were performed on SU1 status, with a range between 23% and 50% ( Fig. 1) . Preoperative recipient and donor characteristics, before and after propensity matching, are summarized in Table 1 and 2. Overall occurrence of severe PGF and 1-year survival were 27% in group SU1 vs 26% in group SL (P = 0.71), and 75% in group SU1 vs 71% in group SL (P = 0.36). After propensity matching, occurrence of severe PGF and 1-year survival were 25% in group SU1 vs 28% in group SL (P = 0.58), and 74% in group SU1 vs 70% in group SL (P = 0.47). After propensity-score multivariable analysis, independent risk factors for 1-year mortality included recipient age above 60 years (OR 2.99, P < 0.01), preoperative recipient mechanical ventilation (OR 3.60, P = 0.04), donor age (OR 1.03, P = 0.02) and sex mismatch (OR 0.49, P = 0.01); SU1 list patients were not at higher risk of post-transplant early death (OR 0.70, P = 0.38) ( Table 3 ). Overall 5-year survival was 69% in group SU1 vs 59% in group SL (P = 0.16) (Fig. 2a) . Five-year survival after propensity matching was 70% in group SU1 vs 57% in group SL (P = 0.19) (Fig. 2b) .
SU1 subgroup analysis
A subgroup analysis was carried out on SU1 patients only: independent risk factors for 1-year mortality were recipient insulindependent diabetes (OR 3.84, P = 0.04), recipient history of vascular disease (OR 7.67, P = 0.02), recipient creatinine (OR 1.01, P < 0.01) and unfavourable sex mismatch (male recipient/female donor, OR 2.62, P < 0.01). Independent risk factors for 5-year survival were recipient insulin-dependent diabetes (HR 2.63, P = 0.01), recipient history of vascular disease (HR 2.70, P = 0.04) and recipient creatinine (HR 1.06, P < 0.01) ( Table 4) .
Period analysis
Significant differences at univariate period analysis of SU1 patients, comparing two eras (Era I, 2005-08 vs Era II, 2009-12), are summarized in Table 5 . When necessary, pretransplant ECMO support in Era II was performed more frequently by peripheral canulation, resulting in a lower rate of prior sternotomies or ventilator-dependent patients. Moreover, renal function was better preserved in SU1 patients during Era II. This could explain the 1-year mortality reduction trend over time: 29% (Era I, 2005-08) vs 22% (Era II, 2009-12), P = 0.23.
Patients who missed SU1 donor allocation
Fifty-three patients missed donor allocation during the SU1 national priority period and were downgraded to the standard waiting list: 10 patients remained stable on list and could wait for cardiac transplantation after a mean of 52 ± 74 (range 6-238) days; 31 patients (among whom 12 were on ECMO) needed long-term VAD circulatory support after a mean of 16 ± 28 (range 0-158) days; 12 patients, under ECMO support, became too sick to be transplanted or supported with VAD, and died after a mean of 22 ± 34 (range 1-122) days. Overall 1-and 5-year survivals of these 53 patients were, respectively, 36% and 29%.
DISCUSSION
Donor allocation systems
Donor heart allocation is a major issue in heart transplantation, because the demand for donor hearts, as the best therapeutic option for end-stage heart failure, has continued to exceed their supply. Various allocation systems have been established in different countries, guided by the rule of organ allocation to patients in greatest need. In the USA, the UNOS adopted a threetier system, ruled by medical urgency: 1A, 1B and 2 statuses. Moreover, UNOS has periodically modified the allocation algorithm to allow a broader regional sharing of available hearts to Status 1A and 1B candidates prior to their allocation to local, less sick candidates [6] . The excellent outcomes of status 1A recipients could be explained by the fact that this high-urgent status includes patients under inotropes or temporary circulatory support together with stable patients supported with TAH or continuousflow Left Ventricular Assist Device (LVAD), which appear to be at low risk of death on waiting list [7] and after cardiac transplantation [8] . The Eurotransplant network also prioritizes patients according to medical urgency and time into a similar tier system: highurgent, urgent and elective patients. A first report favourably supported that policy, which allowed transplantation of high-urgency recipients with an acceptable low-risk [3] . On the other hand, a more recent report pointed out this allocation system, which decreased the proportion of local harvesting, resulting in a longer ischaemic time, without any significant outcome improvement [4] . Furthermore, high-urgent patients maintain their priority status indefinitely until transplantation, ensued by an increasing waiting time and a crowding of recipients in the high-urgent status: as a result, 90% of overall cardiac transplantation activity concerns highurgency recipients [9] . Unlike the Eurotransplant system, duration of SU1 status is limited in time, in order to avoid recipients crowding on the waiting list: in our series, only 38% of recipients have been transplanted according to the SU1 priority waiting list. On the other hand, as Eurotransplant recipients, nearly all SU1 patients underwent heart transplantation under high-dose inotropes and/ or ECMO support. Donor allocation is a key point, as patients under high-dose inotropes and/or ECMO support could not wait for a cardiac graft indefinitely: the main objective of the high urgency allocation system was to improve survival of these patients on the waiting list by allocating hearts to the sickest candidates.
Patient survival benefit was expected because the more critically ill the patient, the greater the survival benefit of transplantation. Drawback is that, as underlined by Dorent et al. [10] , assignment of a priority with direct access for transplantation to sickest patients might improve global patient survival but allocates hearts to patients with sub-optimal post-transplant outcome. As the paradigm of allocating heart donors to critically ill patients was not to waste a precious and limited resource like heart grafts, we were considerably relieved by the outcomes of SU1 patients, similar to those of SL patients.
SU1 recipient and donor characteristics
In our opinion, critical conditions of SU1 patients, such as the circulatory and respiratory supports, were favourably counterbalanced by other recipients and donor characteristics: SU1 recipients were younger, with better renal function, and obviously, more often supported with inotropes or ECMO at the time of transplantation.
We did not specifically take care of patient age at the time of SU1 listing, neither have we restricted listing of older patients for the benefit of youngest recipients, as witnessed by a similar percentage of recipients older than 60 years in both groups. Younger age of SU1 recipients could be explained by the fact that older patients do not tolerate as well acute or decompensate chronic heart failure, and then rapidly become too sick to be listed for heart transplantation. As shown by VanderPluym et al. [11] , older age was a risk factor for being removed from the waiting list due to cardiac recipient deterioration.
Better renal function in SU1 patients might be in connection with the longer history of heart failure in SL patients with more significant stigmata of renal impairment and a higher proportion of patients implanted with an ICD. Also SU1 donors were younger, which explained the related differences in donor size (height, weight and BSA), in a more favourable sex mismatch and in death from a traumatic cause. As we had a very aggressive policy of donor acceptance, especially for SU1 patients, we did not try to match donors and recipients on the basis of age or gender. So, differences in donor age could be explained by variations in allocation between SL and SU1 patients. Donors for SL patients were allocated on a geographybased priority: as a large-volume centre, we often accepted donors previously discarded by low-volume centres, because of donor age or comorbidities. In case of donors for SU1 patients, we took advantage of the medical-based allocation, which more often gives us access to 'first-choice' donors, previously taken by lowvolume centres with a more selective policy for donor acceptance.
As pointed by Haneya et al. [4] , ischaemic time was longer in SU1 group: this is another side effect of the SU1 waiting list, as the geography-based priority was overruled by the urgencybased allocation system, and transplant teams could not take advantage of local donors.
On the other hand, one could argue about 1-and 5-year survivals of SL patients, which are 10-15% lower than in the ISHLT annual report [12] . Inferiority of our results could rely on differences in cardiac donor pool between USA and Europe [13] : in our series donor age was significantly older than in the ISHLT data: 61% of our donors were >50 years, which is greater by far than the 8% currently reported [14, 15] . Moreover, although cardiac donor mean age remained lower than 35 in the USA, it went over this threshold in France since 1995, reaching 45 years for the last 10 years. Nevertheless the continuous progress in recipient and donor management, donor age remains an outmost risk factor for early and late mortality as shown by ISHLT data [12] .
Finally, we could consider many of our donors as marginal donors, especially if we take into the account, as underlined by Zuckermann and Aliabadi [13] , that nearly 90% of our donors needed an inotropic support with a mean dose of norepinephrine of 0.37 mg/kg/min.
Unfortunately, 53 patients had to face the unavailability of cardiac donor during the priority list period: in our early experience, after coming back to the standard list, we unconsciously tended towards waiting for a matched cardiac donor, which could be justified in case of particularly favourable recipient ABO and size characteristics. However, this was clearly the wrong attitude, as complications could occur, jeopardizing further therapeutic options: this explains why patients who missed donor allocation during the priority list period showed very poor outcomes with a grim early and mid-term survival. Nowadays, after missing the slot for the SU1 donor allocation, these patients are straightforward addressed for long-term VAD implantation. Analysis of risk factors for early and 5-year mortality in SU1 patients shows how careful should be patient selection before enrolment on the priority waiting list. In order to limit the loss of heart donor grafts, a priority allocation status should not be granted to older recipients with an impaired renal function or comorbidities like diabetes or vascular disease. These patients should be discussed for an LVAD or TAH implantation.
Period analysis
Period analysis showed how this lesson was early learned, since renal function of recipients at SU1 waiting list enrolment improved in more recent years: indeed, the 'Agence of Biomedecine' promptly recognized the outmost importance of renal function for outcomes of SU1 recipients, avoiding SU1 waiting list enrolment for patients with a glomerular filtration rate lower than 40 ml/min [5] . Finally, it is interesting to point out that 38% of SU1 patients needing a pretransplant ECMO support: overall proportion of more critically ill patients needing pretransplant ECMO support was similar in both eras, whereas type of canulation significantly changed over the years. As other teams [16] , at the beginning of our experience we faced the occurrence of vascular complications at femoral site of canulation, leading in a more frequent deployment of central canulation. A better management of ECMO techniques allowed a safer use of simple peripheral canulation in more recent years, also resulting in an easier management of recipients. 
Limitations
As stated in the Methods section, this study carries all the limits that a retrospective design implies. Even if all data were prospectively collected into the database of the French regulatory agency for transplantation, our analyses were limited to this variables panel. However, the advantages of a prospective design of the study could be limited to a larger or a different choice of recipient and donor variables, as no randomization between stable and high-urgency patients was ethically possible and even desirable.
Comparison between SU1 and SL patients included a propensity score analysis, in order to control for selection bias; nevertheless, as the standard and the SU1 waiting lists represent two different strategies for different patients, our aim was not to demonstrate a superiority of a strategy over another one. Above all, we would make sure against a nonoptimal use of donor cardiac graft, because of their allocation to urgent patients with an expected poor post-transplant outcome, resulting in donor wasting.
CONCLUSIONS
This study represents the largest single-centre report on the French high-urgency waiting list SU1: it confirms that, facing the relative shortage of organ donors, the SU1 waiting list allowed allocating cardiac donors for critically ill patients without increasing early and mid-term mortality. Careful selection of recipients is mandatory in order to improve outcomes. Long-term circulatory VAD implantation should be soon proposed to eligible highurgency patients who missed donor allocation during the priority list period.
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